Abstract
We report on a 42-year-old patient whose relapse of acute promyelocytic leukaemia (APL) included meningeal infiltration. Since he had previously experienced ATRA syndrome, he received arsenic trioxide (ATO) plus intrathecal therapy with cytarabine, prednisone, and methotrexate. We measured the concentration of arsenic in his cerebrospinal fluid (CSF). Arsenic showed a peak CSF concentration of 0.008 mg/l (0.11 μmol/l) and a nadir of 0.002 mg/l (0.027 μmol/l), both representing about 14% of blood levels. ATO thus crosses the blood–CSF-barrier when administered intravenously, but the concentration in CSF is probably not sufficient for treatment of meningeal leukemia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have